Table 2.
Effects of Tacrolimus on the gene expression associated with cardiac hypertrophy-induced by potassium bromate (KBrO3) in H9c2 cells.
| Contents | Control | Vehicle + KBrO3 (250 μM) | Tacrolimus (0.5 μM) + KBrO3 (250 μM) | Tacrolimus (1 μM) + KBrO3 (250 μM) |
|---|---|---|---|---|
| Relative mRNA of ANP/β-Actin | 1.00 ± 0.00 | 1.82 ± 0.08** | 1.33 ± 0.06*# | 1.00 ± 0.05# |
| Relative mRNA of BNP/β-Actin | 1.00 ± 0.00 | 1.84 ± 0.11** | 1.09 ± 0.16*# | 0.78 ± 0.13# |
| Relative mRNA of UBE3A/β-Actin | 1.00 ± 0.00 | 1.87 ± 0.1** | 1.33 ± 0.1*# | 0.72 ± 0.13# |
| Ratio of calcineurin/β-Actin protein | 0.23 ± 0.02 | 0.76 ± 0.06** | 0.57 ± 0.03*# | 0.30 ± 0.03# |
| Ratio of NFAT3/Histone H3 protein | 0.28 ± 0.02 | 0.84 ± 0.06** | 0.52 ± 0.06*# | 0.36 ± 0.03# |
| Ratio of UBE3A/β-Actin protein | 0.41 ± 0.05 | 0.81 ± 0.06** | 0.65 ± 0.03*# | 0.45 ± 0.04# |
Values (mean ± SEM) were obtained from six samples per group. Effects of Tacrolimus at indicated concentration were compared with that treated with vehicle.
*
P < 0.05 or
**
P < 0.01 significantly different from the control.
#
P < 0.05 varied with the vehicle-treated group.